Pay in 4 interest-free payments of $6.75 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
Tirzepatide Research: Published trials of FDA-approved tirzepatide have shown it acts as a dual GLP-1/GIP receptor agonist, targeting both the GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) pathways
Flexible Options We offer multiple GLP-1 program tiers (GLP-1, GLP-2, GLP-3) based on dosing and support level, weekly payment plans for easier budgeting, in-office or at-home injection options, and the ability to combine with other peptide therapies for enhanced results
Tc dng ph thng gp ca thuc Semaglutide Bun nn, nn
10.1637/10426-101712-Reg.1 223
Patients with Prediabetes The SCALE Obesity and Prediabetes trial found that liraglutide 3.0 mg reduced the rate of progression from prediabetes to type 2 diabetes by 79% over 56 weeks (hazard ratio 0.21, 95% CI 0.13 to 0.34) [1]
US$ 26.72
US$ 26.19
US$ 25.41
US$ 28.68
US$ 28.90
